Showing 5 posts of 5 posts found.


FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS

August 30, 2023
Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …


Canadian approval for Reblozyl for transfusion-dependent anaemia in beta-thalassemia patients

September 29, 2020
Manufacturing and Production, Sales and Marketing BMS, Canada, Reblozyl

Bristol Myers Squibb and Acceleron have managed to secure regulatory approval in Canada for Reblozyl (luspatercept) for the treatment of …


Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations

May 1, 2020
Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …


FDA approval for BMS and Acceleron’s Reblozyl to reduce red blood cell transfusion dependence

April 6, 2020
Manufacturing and Production, Sales and Marketing BMS, FDA, Reblozyl, pharma

The FDA has given the regulatory thumbs-up in the US of Reblozyl (luspatercept-aamt), the “first and only erythroid maturation agent” …

Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia

November 11, 2019
Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma

The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …

Latest content